NRX Pharmaceuticals, Inc.

Afternoon ladies and gentlemen and welcome to the NRX Pharmaceuticals first quarter 2025 earnings call. At this time all lines are in a less lonely mode. Following the presentation we will conduct a question and answer session. If at any time during this call you require immediate assistance please press star zero for the operator. This call is being recorded on Thursday May 15, 2025. I would now like to turn the conference over to Matthew Duffy, Chief Business Officer. Please go ahead.

Thank you, Andrew, and welcome, everyone.

Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties because they could cause actual results to differ materially from historical experience or permanent expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the FTC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued today and the company's Form 10-Q, which may be accessed from the Investors page of the NRF Pharmaceuticals website. Joining me today on the call are Jonathan Javits, our founder, chairman, and CEO, and Michael Abrams, our chief financial officer. Dr. Javits will provide an overview of our company's progress as reported in today's Form 10Q, following which Mike will review our company's financial results. Following their prepared remarks, we will address investor questions. I will now turn the call over to Jonathan. Jonathan?